Zilovertamab
Showing 1 - 8 of 8
Lymphoma, Mantle-Cell, Lymphoma, Lymphoproliferative Disorders Trial (Zilovertamab, Ibrutinib, Placebo)
Not yet recruiting
- Lymphoma, Mantle-Cell
- +7 more
- Zilovertamab
- +2 more
- (no location specified)
Jun 21, 2022
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,
Recruiting
- Chronic Lymphocytic Leukemia
- +3 more
- Zilovertamab vedotin
- Nemtabrutinib
-
Spokane, Washington
- +1 more
Aug 12, 2022
Lymphoma, Large B-Cell, Diffuse (DLBCL) Trial in Jerusalem, Seoul, Warszawa (Zilovertamab Vedotin, Cyclophosphamide,
Recruiting
- Lymphoma, Large B-Cell, Diffuse (DLBCL)
- Zilovertamab Vedotin
- +6 more
-
Victoria, British Columbia, Canada
- +19 more
Jan 19, 2023
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in United States (Zilovertamab vedotin)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +11 more
- Zilovertamab vedotin
-
Duarte, California
- +13 more
Jan 12, 2023
DLBCL, DLBCL Trial in Worldwide (Zilovertamab vedotin, Rituximab, Gemcitabine)
Recruiting
- DLBCL
- Diffuse Large B-Cell Lymphoma
- Zilovertamab vedotin
- +4 more
-
Whittier, California
- +21 more
Nov 30, 2022
Relapsed or Refractory DLBCL Trial in Worldwide (MK-2140 (zilovertamab vedotin))
Recruiting
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- MK-2140 (zilovertamab vedotin)
-
Orange, California
- +38 more
Aug 12, 2022
Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)
Recruiting
- Urothelial Carcinoma
- Zilovertamab vedotin
-
Cleveland, Ohio
- +11 more
Jan 25, 2023
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (Cirmtuzumab (2-16
Recruiting
- B-cell Chronic Lymphocytic Leukemia
- +3 more
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
- +5 more
-
Duarte, California
- +12 more
Jun 16, 2022